デフォルト表紙
市場調査レポート
商品コード
1748864

ロサルタン市場- 世界の産業規模、シェア、動向、機会、予測、供給源別、用途別、地域別、競合別、2020～2030年

Losartan Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Source, By Application, By Region and Competition, 2020-2030F

出版日
ページ情報
英文 185 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=155.10円

こちらのレポートには、数時間（ご購入金額の10%）分のアナリストへの質問／追加調査サービスが含まれております。

ロサルタン市場- 世界の産業規模、シェア、動向、機会、予測、供給源別、用途別、地域別、競合別、2020～2030年
出版日: 2025年06月13日
発行: TechSci Research
ページ情報: 英文 185 Pages
納期: 2～3営業日
GIIご利用のメリット

  • 全表示

  • 概要
  • 目次
概要

ロサルタンの世界市場は、2024年に7億2,850万米ドルと評価され、2030年には8億9,816万米ドルに達し、CAGR 3.75%で成長すると予測されています。

アンジオテンシンII受容体拮抗薬（ARB）であるロサルタンは、高血圧、心不全、糖尿病性腎症の管理に広く処方されています。その臨床的有効性、手ごろな価格、安全性プロファイルにより、世界の多様なヘルスケアシステムで幅広く使用されています。肥満症、高血圧症、2型糖尿病などの生活習慣病、特に高齢化社会の負担の増大は、ロサルタンのような降圧薬に対する需要を著しく高めています。さらに、慢性疾患の予防に関する社会的意識の高まり、ジェネリック医薬品分野の成長、身近な治療の促進が、市場の拡大をさらに後押ししています。しかし、汚染に関連した製品回収や、激しいジェネリック医薬品競争による持続的な価格圧力といった課題が、一部のメーカーの収益性を弱めています。こうした制約にもかかわらず、ロサルタンは成熟市場、新興市場のいずれにおいても、心血管系治療の主力製品であり続けています。

市場概要
予測期間 2026-2030
市場規模：2024年 7億2,850万米ドル
市場規模：2030年 8億9,816万米ドル
CAGR：2025年～2030年 3.75%
急成長セグメント 製造受託機関
最大市場 北米

市場促進要因

ヘルスケア産業の成長

主な市場課題

サプライチェーンの混乱

主要市場動向

併用療法の調査増加

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 COVID-19が世界のロサルタン市場に与える影響

第5章 世界のロサルタン市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェア・予測
    • 供給源別（製造受託機関、社内）
    • 用途別（高血圧、脳卒中、糖尿病性腎症、その他）
    • 地域別
    • 企業別（2024）
  • 市場マップ

第6章 北米のロサルタン市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 北米：国別分析
    • 米国
    • メキシコ
    • カナダ

第7章 欧州のロサルタン市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 欧州：国別分析
    • フランス
    • ドイツ
    • 英国
    • イタリア
    • スペイン

第8章 アジア太平洋地域のロサルタン市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • アジア太平洋地域：国別分析
    • 中国
    • インド
    • 韓国
    • 日本
    • オーストラリア

第9章 南米のロサルタン市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 南米：国別分析
    • ブラジル
    • アルゼンチン
    • コロンビア

第10章 中東・アフリカのロサルタン市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 中東・アフリカ：国別分析
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦

第11章 市場力学

  • 促進要因
  • 課題

第12章 市場動向と発展

  • 合併と買収
  • 製品上市
  • 最近の動向

第13章 混乱：紛争、パンデミック、貿易障壁

第14章 世界のロサルタン市場：SWOT分析

第15章 ポーターのファイブフォース分析

  • 業界内の競合
  • 新規参入の可能性
  • サプライヤーの力
  • 顧客の力
  • 代替品の脅威

第16章 競合情勢

  • Merck & Co. Inc.
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi S.A.
  • Novartis International AG
  • Dr. Reddy's Laboratories Ltd.
  • Sun Pharmaceuticals Industries Ltd.
  • Aurobindo Pharma Ltd.
  • Torrent Pharmaceutical Ltd.
  • Lupin Ltd.

第17章 戦略的提言

第18章 調査会社について・免責事項

目次
Product Code: 7269

The Global Losartan Market was valued at USD 728.50 Million in 2024 and is projected to reach USD 898.16 Million by 2030, growing at a CAGR of 3.75%. Losartan, an angiotensin II receptor blocker (ARB), is extensively prescribed for managing hypertension, heart failure, and diabetic nephropathy. Its clinical efficacy, affordability, and safety profile have contributed to its broad utilization across diverse global healthcare systems. The growing burden of lifestyle-related illnesses such as obesity, hypertension, and type 2 diabetes-especially among aging populations-has significantly bolstered demand for antihypertensive medications like losartan. Additionally, increasing public awareness around chronic disease prevention, the growth of the generic pharmaceutical sector, and the promotion of accessible treatments are further propelling market expansion. However, challenges such as product recalls linked to contamination and sustained pricing pressures due to intense generic competition have tempered profitability for some manufacturers. Despite these constraints, losartan remains a mainstay in cardiovascular therapy across both mature and emerging markets.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 728.50 Million
Market Size 2030USD 898.16 Million
CAGR 2025-20303.75%
Fastest Growing SegmentContract Manufacturing Organizations
Largest MarketNorth America

Key Market Drivers

Growth in Healthcare Industry

The robust expansion of the global healthcare sector, with annual sales surpassing USD 4 trillion, continues to drive the growth of the losartan market. Key segments such as pharmaceuticals and biotechnology account for over USD 850 billion, while diagnostics and medical technology contribute more than USD 400 billion. As healthcare systems worldwide scale up to meet the rising prevalence of chronic conditions, there is heightened focus on early intervention and long-term management strategies for cardiovascular and renal diseases. This has elevated the demand for effective antihypertensive agents, with losartan positioned as a first-line option due to its efficacy in managing blood pressure and reducing the risk of stroke and kidney damage in diabetic patients. Increased healthcare spending, particularly in developing countries, along with broader access to generics, is further accelerating market growth.

Key Market Challenges

Disruption in Supply Chain

Supply chain disruptions pose a persistent challenge to the global losartan market, impacting the availability and timely distribution of both active pharmaceutical ingredients (APIs) and finished formulations. The production of losartan heavily depends on stable API sourcing, predominantly from manufacturing hubs in India and China. Any disruption caused by regulatory non-compliance, factory shutdowns, environmental restrictions, or geopolitical tensions can lead to delays and shortages. In addition, reliance on limited global suppliers creates bottlenecks, especially during periods of heightened demand. These interruptions not only affect drug availability but can also lead to price fluctuations, undermining supply chain resilience and complicating inventory management for manufacturers and healthcare providers alike.

Key Market Trends

Increasing Research into Combination Therapies

A growing trend shaping the losartan market is the increasing focus on fixed-dose combination therapies for the treatment of hypertension and related cardiovascular disorders. With the complexity of disease management rising, pharmaceutical companies are exploring synergistic formulations that combine losartan with complementary antihypertensive agents such as hydrochlorothiazide or amlodipine. These combination therapies aim to improve therapeutic outcomes, simplify dosing regimens, and boost patient adherence. Inspired by successful models in oncology and other chronic disease areas, this trend is supported by clinical data demonstrating enhanced efficacy and patient satisfaction. Fixed-dose combinations also offer pharmaceutical companies a pathway to differentiate their products in a competitive generic market, helping to extend product lifecycles and align with evolving clinical guidelines that prioritize combination treatment strategies.

Key Market Players

  • Merck & Co. Inc.
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi S.A.
  • Novartis International AG
  • Dr. Reddy's Laboratories Ltd.
  • Sun Pharmaceuticals Industries Ltd.
  • Aurobindo Pharma Ltd.
  • Torrent Pharmaceutical Ltd.
  • Lupin Ltd.

Report Scope

In this report, the Global Losartan Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Losartan Market, By Source:

  • Contract Manufacturing Organizations
  • In-House

Losartan Market, By Application:

  • Hypertension
  • Stroke
  • Diabetic Nephropathy
  • Others

Losartan Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Losartan Market.

Available Customizations

Global Losartan Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, and Trends

4. Impact of COVID-19 on Global Losartan Market

5. Global Losartan Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Source (Contract Manufacturing Organizations, In-House)
    • 5.2.2. By Application (Hypertension, Stroke, Diabetic Nephropathy, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2024)
  • 5.3. Market Map

6. North America Losartan Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Source
    • 6.2.2. By Application
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Losartan Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Source
        • 6.3.1.2.2. By Application
    • 6.3.2. Mexico Losartan Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Source
        • 6.3.2.2.2. By Application
    • 6.3.3. Canada Losartan Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Source
        • 6.3.3.2.2. By Application

7. Europe Losartan Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Source
    • 7.2.2. By Application
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Losartan Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Source
        • 7.3.1.2.2. By Application
    • 7.3.2. Germany Losartan Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Source
        • 7.3.2.2.2. By Application
    • 7.3.3. United Kingdom Losartan Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Source
        • 7.3.3.2.2. By Application
    • 7.3.4. Italy Losartan Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Source
        • 7.3.4.2.2. By Application
    • 7.3.5. Spain Losartan Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Source
        • 7.3.5.2.2. By Application

8. Asia Pacific Losartan Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Source
    • 8.2.2. By Application
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Losartan Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Source
        • 8.3.1.2.2. By Application
    • 8.3.2. India Losartan Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Source
        • 8.3.2.2.2. By Application
    • 8.3.3. South Korea Losartan Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Source
        • 8.3.3.2.2. By Application
    • 8.3.4. Japan Losartan Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Source
        • 8.3.4.2.2. By Application
    • 8.3.5. Australia Losartan Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Source
        • 8.3.5.2.2. By Application

9. South America Losartan Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Source
    • 9.2.2. By Application
    • 9.2.3. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Losartan Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Source
        • 9.3.1.2.2. By Application
    • 9.3.2. Argentina Losartan Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Source
        • 9.3.2.2.2. By Application
    • 9.3.3. Colombia Losartan Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Source
        • 9.3.3.2.2. By Application

10. Middle East and Africa Losartan Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Source
    • 10.2.2. By Application
    • 10.2.3. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Losartan Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Source
        • 10.3.1.2.2. By Application
    • 10.3.2. Saudi Arabia Losartan Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Source
        • 10.3.2.2.2. By Application
    • 10.3.3. UAE Losartan Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Source
        • 10.3.3.2.2. By Application

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Disruptions : Conflicts, Pandemics and Trade Barriers

14. Global Losartan Market: SWOT Analysis

15. Porters Five Forces Analysis

  • 15.1. Competition in the Industry
  • 15.2. Potential of New Entrants
  • 15.3. Power of Suppliers
  • 15.4. Power of Customers
  • 15.5. Threat of Substitute Products

16. Competitive Landscape

  • 16.1. Merck & Co. Inc.
    • 16.1.1. Business Overview
    • 16.1.2. Company Snapshot
    • 16.1.3. Products & Services
    • 16.1.4. Financials (As Reported)
    • 16.1.5. Recent Developments
    • 16.1.6. Key Personnel Details
    • 16.1.7. SWOT Analysis
  • 16.2. Pfizer Inc.
  • 16.3. Teva Pharmaceutical Industries Ltd.
  • 16.4. Sanofi S.A.
  • 16.5. Novartis International AG
  • 16.6. Dr. Reddy's Laboratories Ltd.
  • 16.7. Sun Pharmaceuticals Industries Ltd.
  • 16.8. Aurobindo Pharma Ltd.
  • 16.9. Torrent Pharmaceutical Ltd.
  • 16.10. Lupin Ltd.

17. Strategic Recommendations

18. About Us & Disclaimer